Trials / Unknown
UnknownNCT01857544
Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy
Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES)
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Tennessee Retina · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is determine the number of patients with complete resolution of macular edema secondary to central retinal vein occlusion following 6 monthly injections of Aflibercept.
Detailed description
Twenty (20) consented participant who meet the inclusion criteria will be enrolled to be followed for 6 months. All subjects will receive monthly 2.0 mg intravitreal aflibercept injections.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept | Monthly 2.0mg Aflibercept Intravitreal Injection |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2016-01-01
- Completion
- 2016-03-01
- First posted
- 2013-05-20
- Last updated
- 2014-10-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01857544. Inclusion in this directory is not an endorsement.